Aptose Biosciences Inc. (APTOF)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenue | - | - | ||
| Research and development | 3,298 | 2,364 | ||
| General and administrative | 3,623 | 3,097 | ||
| Operating expenses | 6,921 | 5,461 | ||
| Interest (expense) income | -110 | -84 | ||
| Foreign exchange loss | -12 | 2 | ||
| Total other (loss) income | -122 | -82 | ||
| Net loss | -7,043 | -5,543 | ||
| Unrealized loss on available-for-sale securities | - | - | ||
| Total comprehensive loss | -7,043 | -5,543 | ||
| Earnings per share, diluted | -2.76 | -2.61 | ||
| Net loss per share - basic | -2.76 | -2.61 | ||
| Weighted-average common shares - basic | 2,552,429 | 2,126,287 | ||
| Weighted-average common shares - diluted | 2,552,429 | 2,126,287 | ||